Shasun Pharmaceuticals | Latest & Breaking News on Shasun Pharmaceuticals | Photos, Videos, Breaking Stories and Articles on Shasun Pharmaceuticals

Bondholders of Suzlon Energy plan legal action post default: Report

As banks are unlikely to take a steep haircut on their Rs 10,300 crore exposure, an informal deal with Brookfield seems to be off the table

Modi to address annual gala of USIBC next month

Modi's address to the USIBC before who's who of American corporate sector would be on June 7. He will also participate in a roundtable with leading global CEOs, USIBC said.

Market valuation of top-5 cos declines by Rs 38,969 cr

The combined market valuation of five of the top-10 most valued Indian companies declined by Rs 38,969 crore last week.

Buy Jubilant Foodworks, Wockhardt: Ashwani Gujral

Ashwani Gujral of ashwanigujral.com advises buying Jubilant Foodworks and Wockhardt.

Prefer Aurobindo, Ajanta Pharma, Torrent Pharma: Gujral

Ashwani Gujral of ashwanigujral.com is of the view that one may prefer Aurobindo Pharma, Ajanta Pharma and Torrent Pharma and likes Glenmark Pharma.

Hold Sun Pharma; target of Rs 845: ICICIDirect

ICICIDirect has recommended hold rating on Sun Pharma with a target price of Rs 845 in its research report dated February 15, 2016.

Top buzzing midcap stocks to trade on January 29

Here are a few top buzzing midcap stocks picked by CNBC-TV18's analysts in trade today. We have Yes Bank, Just Dial, Sun Pharma, ICICI Bank, Apar Ind, Tide Water Oil, Glenmark, Titan, TVS Motors and Himatsingka Seige.

India formulation; Maintain healthy growth: PrabhudasLilladher

Prabhudas Lilladher has come out with its sector report on Pahrma Sector dated January 14, 2016. According to the research firm,IPM grows 11.9% in December, maintains longâ€term average growth, says the report

Buy Sun Pharma; target of Rs 920:Edelweiss

Edelweiss is bullish on Sun Pharma and has recommended buy rating on the stock with a target price of Rs 920 in its research report dated December 22, 2015.

Top buzzing midcap stocks to trade on December 23

Here are a few top buzzing midcap stocks picked by CNBC-TV18's analysts in trade today. We have - Essar Oil, Sun Pharmaceuticals, Dr Lal PathLabs, Alkem Laboratories, Pidilite, Jaypee Infratech, Pilani, Opto Circuits, Chambal Fertiliser, Welspun Enterprises, and Prestige Estates.

Midcaps to shine; auto and pharma key themes: Dimensions

Ajay Srivastava of Dimensions Capital says the pharma sector will give good returns from a 3-5 year perspective.

Buy Sun Pharmaceutical, says Sukhani

According to Sudarshan Sukhani of s2analytics.com, one may buy Sun Pharma.

Like Strides Arcolab for long term, says Deepak Shenoy

Deepak Shenoy of Capitalmind.in likes Strides Arcolab for the long term.

Don‘t get carried away by bounce back, be cautious: Bhamre

Siddarth Bhamre, Head Equity Derivatives at Angel Broking cautions that one should not get carried away by the bounce back in the market. Nifty has some very strong resistance around 8100-8150.

Buy Coral Laboratories on dips, says Prakash Diwan

According to Prakash Diwan of prakashdiwan.in, one may buy Coral Laboratories on dips.

Super Six stocks that can boost your portfolio on Nov 23

Ashish Kyal of wavesstrategy.com advises buying Petronet LNG with a target of Rs 243.

Strides Shasun seek fresh approval to raise up to Rs 1500cr

The company has called for an extraordinary general meeting on December 12 to discuss the proposal to raise the money.

Jubilant Life Sciences may test Rs 570, says Ajay Bodke

Ajay Bodke of Prabhudas Lilladher feels that Jubilant Life Sciences may test Rs 570 and Glenmark Pharma may go up to Rs 1186.

Sentiment to turn +ve for L&T in H2; buy IRB: Macquaire

The government Wednesday authorised NHAI to pay compensation to road developers, in case of delays not attributable to them, a move that will significantly benefit 34 stuck projects.

Buy Sun Pharma; target of Rs 950: Angel Broking

Angel Broking is bullish on Sun Pharma and has recommended buy rating on the stock with a target of Rs 950 in its November 17, 2015 research report.

Shasun Pharma up 2.5% on USFDA nod for muscle-relaxant drug

"While the 350 mg has a few generic players, Shasun expects to be the first marketed generic player in the USD 16 million Carisoprodol tablets of 250 mg opportunity," it added.

Shasun Pharma gets US FDA nod to market Carisoprodol

In a BSE filing, Shasun Pharmaceuticals said, "It has received approval from the United States Food and Drug Administration (US FDA) for Carisoprodol tablets." The approval is for the 250 mg and 350 mg strengths. Shasun Pharma said Carisoprodol tablets of 250 mg and 350 mg have sales of approximately USD 38 million.

15 quality stocks for Samvat 2072: AB Money

For SAMVAT 2072, AB Money recommends a portfolio of 15 quality businesses/companies, which are mix of cyclicals, new emerging sectors and consumption with strong earnings growth momentum. Expect these stocks to deliver returns in the range of 20-25% over next 6-12 months, says the report.